FDA Approval for Tisotumab Vedotin in Advanced Cervical Cancer FDA Approval for Tisotumab Vedotin in Advanced Cervical Cancer

Tisotumab vedotin-tftv (Tivdak), an antibody-drug conjugate, has been granted accelerated approval for the treatment of recurrent or metastatic cervical cancer.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news